(Q48254303)

English

Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest.

scientific article published on 14 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest. (English)

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

phase III clinical trial

0 references

author name string

P-M Girard

1

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

T B Campbell

2

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

B Grinsztejn

3

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

J Hartikainen

4

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

A Rachline

5

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

S Nijs

6

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

J Witek

7

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

publication date

14 March 2012

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

13

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

7

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

427-435

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00994.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2012.00994.X

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/22413938

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48254303&oldid=1765884823"